Case Report

Orally Disintegrating Olanzapine for the Treatment of Psychotic and Behavioral Disturbances Associated with Dementia

Authors: Roy R. Reeves, DO, PHD, Rafael A. Torres, MD

Abstract

Orally disintegrating olanzapine is a recently marketed form of olanzapine that dissolves rapidly on contact with saliva. We describe six demented patients resistant to treatment with common oral antipsychotic medications who were successfully treated with the formulation. The importance of these case reports is to make physicians aware that orally disintegrating olanzapine may be useful for the management of psychobehavioral disturbances in demented patients who resist or have difficulty taking standard oral medications.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Yeager BF, Farnett LE, Ruzicka SA. Management of the behavioral manifestations of dementia. Arch Intern Med 1995; 155: 250–260.
 
2. Rovner BW, Kafonek S, Filipp L, Lucas MJ, Folstein MF. Prevalence of mental illness in a community nursing home. Am J Psychiatry 1986; 143: 1446–1449.
 
3. Tariot PN, Podgorski CA, Blazina L, Leibovici A. Mental disorders in the nursing home: Another perspective. Am J Psychiatry 1993; 150: 1063–1069.
 
4. Clark WS, Street JS, Feldman PD, Breier A. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. J Clin Psychiatry 2001; 62: 34–40.
 
5. Satterlee WG, Reams SG, Burns PR, Hamilton S, Tran PV, Tollefson GD. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients. Psychopharmacol Bull 1995; 31: 534(abstr).
 
6. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial—The HGEU Study Group. Arch Gen Psychiatry 2000; 57: 968–976.
 
7. Kay SR, Opler LA, Fizbein A. The Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY, Multi-Health System, 1986.
 
8. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.
 
9. Jones B, Chue P, Adams C. Use of olanzapine rapidly disintegrating tablet in schizophrenia. Schizophrenia Res 1999; 36: 283(abstract).